Respiratorius AB (publ) (RESP.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 2.17 (+5.85%) as of
Key statistics
- Market cap
- 17.15M
- EPS (TTM)
- -0.8400
- Dividend yield
- 0.00%
- 52-week range
- 1.1900 – 3.5400
- Beta
- 1.67
- Revenue (TTM)
- 30.07k
- Profit margin
- 0.00%
- Volume
- 229.00
About Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. Its products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. The company was incorporated in 1998 and is based in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lund, Sweden
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.